FDA approves Emcitate as first treatment for MCT8 deficiency
The FDA has approved Emcitate as the first treatment for MCT8 deficiency, providing a therapy for the peripheral thyrotoxicosis associated with this ultra-rare genetic disorder.
Emcitate (tiratricol) is approved for adults and paediatric patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome.
The first-in-disease approval provides a treatment designed to act without relying on the defective MCT8 transporter responsible for the disorder.
Field | Content |
Article Type | Approvals |
Drug Name | Tiratricol |
Brand Name | Emcitate |
Regulatory Authority | U.S. Food and Drug Administration |
Approval Type | First FDA-approved treatment for MCT8 deficiency |
Indication | Peripheral thyrotoxicosis in adults and paediatric patients with MCT8 deficiency |
Therapy Areas | Rare disease; endocrinology; neurology |
Disease | MCT8 deficiency / Allan-Herndon-Dudley syndrome |
Technology/Modality | Thyroid hormone analogue |
Geography | United States |
What Happened | The FDA approved Emcitate for peripheral thyrotoxicosis in adults and paediatric patients with MCT8 deficiency. |
Why It Matters | Emcitate is the first FDA-approved treatment for MCT8 deficiency, addressing an ultra-rare genetic disorder with no previously approved therapy. |
Supporting Context | MCT8 deficiency results from defects in the MCT8 thyroid hormone transporter and is also known as Allan-Herndon-Dudley syndrome. |
Potential Impact | The approval establishes the first US pharmacological treatment option for patients with MCT8 deficiency. |
Key Takeaway | Emcitate becomes the first FDA-approved treatment for MCT8 deficiency. |
What to Watch | US launch, patient access and longer-term evidence from treatment in adults and children. |
Primary Source | U.S. Food and Drug Administration |
Relevant Date | 28 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments